Cancer Clinical Benefit Tool Needed For Local Therapies -IntraDose Cmte

An effective tool needs to be developed to assess the clinical benefit of local cancer therapies, FDA's Oncologic Drugs Advisory Committee concluded Sept. 10 in voting down Matrix' IntraDose.